19 November 1986
INTERIM COMMERCIAL ITEM DESCRIPTION
BECLOMETHASONE DIPROPIONATE INHALATION AEROSOL, NASAL
The General Services Administration has authorized the use of this Interim Commercial Item Description which was developed by DLA, Defense Personnel Support Center, Directorate of Medical Materiel, DPSC-RST, 2800 South 20th Street, Philadelphia, PA 19101, based upon currently available technical information.
Shall be Beclomethasone Dipropionate Inhalation Aerosol, Nasal.
Shall be a microcrystalline suspension of Beclomethasone Dipropionate-Trichloromonofluromethane clathrate in aerosol propellants suitable for intranasal inhalation.
The valve shall deliver in each metered dose a quantity of clathrate equivalent to 42 mg of Beclomethasone Dipropionate within the applicable assay limits.
Each container shall deliver not less than 200 metered dose.
For type I, shall be therapeutically equivalent to Beclomethasone Dipropionate by Glaxo, Inc. at the same dosage and administration schedule.
For type II, shall be therapeutically equivalent to Beclomethasone Dipropionate by Schering, Inc. at the same dosage and administration schedule.
Workmanship. The product shall be free from defects which detract from its appearance or impair its serviceability.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business